CCR5 inhibitors are indicated for HIV infection and have been in clinical trials for a variety of other autoimmune diseases, including rheumatoid arthritis, graft-versus-host disease, and primary sclerosing cholangitis[37]. The gene discussed is CCR5; the disease is HIV infectious disease.